ABEO Logo

Abeona Therapeutics Inc. (ABEO) 

NASDAQ
Market Cap
$246.92M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
230 of 958
Rank in Industry
143 of 549

Largest Insider Buys in Sector

ABEO Stock Price History Chart

ABEO Stock Performance

About Abeona Therapeutics Inc.

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye …

Insider Activity of Abeona Therapeutics Inc.

Over the last 12 months, insiders at Abeona Therapeutics Inc. have bought $241,836 and sold $269,416 worth of Abeona Therapeutics Inc. stock.

On average, over the past 5 years, insiders at Abeona Therapeutics Inc. have bought $226,097 and sold $1.07M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Seshadri Vishwas (Chief Executive Officer) — $119,800. Alland Leila (director) — $103,598. Vazzano Joseph Walter (Chief Financial Officer) — $35,218.

The last purchase of 11,000 shares for transaction amount of $51,799 was made by Alland Leila (director) on 2024‑05‑16.

List of Insider Buy and Sell Transactions, Abeona Therapeutics Inc.

2024-06-18Saledirector
25,821
0.0635%
$4.51$116,453+29.07%
2024-06-18Saledirector
25,890
0.0637%
$4.51$116,764+29.07%
2024-05-16Purchasedirector
11,000
0.0286%
$4.71$51,799+20.78%
2024-04-26Purchasedirector
7,550
0.0265%
$3.28$24,764+69.33%
2024-04-25PurchaseChief Executive Officer
10,000
0.0343%
$3.20$32,000+72.10%
2024-04-25PurchaseChief Financial Officer
5,608
0.0189%
$3.14$17,609+72.10%
2024-04-25PurchaseSVP, General Counsel
8,600
0.0299%
$3.24$27,864+72.10%
2024-02-06PurchaseChief Executive Officer
20,000
0.0784%
$4.39$87,800+36.98%
2024-01-17Saledirector
7,084
0.0285%
$5.11$36,199+12.20%
2023-09-27Saledirector
5,508
0.022%
$3.91$21,542+20.96%
2023-09-27Saledirector
6,330
0.0252%
$3.91$24,721+20.96%
2023-09-27Saledirector
7,246
0.0288%
$3.90$28,270+20.96%
2023-09-27Saledirector
8,330
0.0417%
$4.91$40,924+20.96%
2023-09-27Saledirector
6,316
0.0252%
$3.91$24,724+20.96%
2023-09-27PurchaseChief Executive Officer
20,000
0.083%
$4.07$81,400+20.96%
2023-09-20Saledirector
327
0.0014%
$3.90$1,275+25.53%
2023-09-19PurchaseChief Financial Officer
3,000
0.0122%
$3.82$11,458+25.59%
2023-09-18PurchaseSVP, General Counsel
3,000
0.0125%
$3.80$11,400+29.70%
2023-06-20Saledirector
338
0.0039%
$4.45$1,504-3.52%
2023-04-25Saledirector
887
0.0105%
$3.25$2,883+31.60%

Insider Historical Profitability

<0.0001%
Seshadri VishwasChief Executive Officer
538260
1.2382%
$5.6830
Vazzano Joseph WalterChief Financial Officer
233868
0.538%
$5.6830<0.0001%
O'Malley Brendan M.SVP, General Counsel
188718
0.4341%
$5.6845<0.0001%
Alland Leiladirector
82857
0.1906%
$5.6811
Charles Faith L.director
78323
0.1802%
$5.6811

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Adage Capital Partners Gp L L C$23.56M7.933.25M0%+$00.04
Nantahala Capital Management Llc$16.75M5.642.31M+2.68%+$437,813.000.78
Millennium Management LLC$14.4M4.851.99M+40.03%+$4.12M0.01
Western Standard Llc$9.87M3.321.36M+68.48%+$4.01M13.34
The Vanguard Group$7.99M2.691.1M+0.07%+$5,995.75<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.